MedTrace Logo

Antidepressant Therapy for Bipolar II Major Depression

NCT00641927 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2008-03-24

No results posted yet for this study

Summary

This study examines the relative safety and benefit of antidepressant therapy (versus recommended mood stabilizer therapy)of bipolar type II major depressive episode. We hypothesize that antidepressant therapy will be superior to mood stabilizer therapy with little or no difference in treatment emergent manic symptoms.

Conditions

  • Bipolar Type II Disorder

Interventions

DRUG

Venlafaxine

37.5 mg - 375 mg daily, 12 Weeks

DRUG

Lithium Carbonate

300 mg - 2100 mg daily, 12 weeks

Sponsors & Collaborators

  • Stanley Medical Research Institute

    lead OTHER

Principal Investigators

  • Jay D Amsterdam, MD · Depression Research Unit, School of Psychiatry, University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-30
Primary Completion
2006-10-31
Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00641927 on ClinicalTrials.gov